Objective: Behçet's disease (BD) is an immunoin-flammatory vasculitis with an unknown etiopathogenesis. Vascular endothelial growth factor (VEGF) is a cytokine-stimulating angiogenesis. It has been suggested to play a role in inflammation and pathogenesis of vasculitic processes.
Study Design: VEGF and CD34 expressions were assessed in samples taken from oral aphthous lesions. The patients were evaluated for disease activity, duration of lesions, serum C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR).
Results: Twenty-six patients were included. Fourteen (53.9%) had increased CRP levels and 12 (46.1%) had increased ESR levels. Positive VEGF and CD34 staining were detected in 46.2% and 69.2% of biopsy samples, respectively. There was good positive correlation between them. The frequency of positive VEGF and CD34 staining was statistically higher in lesions with a duration of more than 6 days. No correlation was found between positive VEGF staining and serum CRP level, ESR and disease activity.
Conclusion: Increased VEGF expression in correlation with CD34 positivity in oral aphthous lesions may show the role of VEGF in pathogenesis of these vasculitic lesions. We have concluded that VEGF may play a role during the course of oral aphthous lesions in BD.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy of thyme honey in the management of oral aphthous ulcers: A randomized controlled clinical trial.
Eur J Oral Sci
December 2024
Oral Medicine and Periodontology, Faculty of Dentistry, Galala University, Suez, Egypt.
The current study aimed to assess the effect of thyme honey on pain relief in patients with minor aphthous ulcers as a primary objective, its healing effect on ulcer size reduction, and the Oral Health Impact Profile (OHIP-14). In this randomized clinical trial, 30 patients (15 in each group) having minor aphthous ulcers at the oral diagnostic clinic at the British University in Egypt were treated with either thyme honey or triamcinolone acetonide in orabase. Different clinical parameters were recorded for both groups at various intervals, such as pain intensity using the Visual Analog Scale (VAS), size of ulcers in mm, and OHIP-14.
View Article and Find Full Text PDFWound healing potential of mouth gel containing isopimarane diterpene from rhizomes for treatment of oral stomatitis.
PeerJ
December 2024
Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Background: Oral ulcers have an impact on 25% of the global population including patients who are suffering from chemotherapy and radiotherapy treatments. L. has been traditionally used for treatment of mouth sores and tongue blisters.
View Article and Find Full Text PDFOral manifestations of Crohn disease managed with ustekinumab: A case report.
J Am Dent Assoc
December 2024
Background: The authors reviewed a case involving the orofacial manifestations of Crohn disease (CD) in an adolescent whose treatment was ultimately managed with a newer class of biologic drug agent, ustekinumab (Stelara, Janssen Biotech). CD is a chronic inflammatory condition affecting the gastrointestinal tract that often causes extraintestinal complications. The underlying etiology of CD involves genetic, environmental, and local factors.
View Article and Find Full Text PDFCase report: HLA-B35-associated optic neuritis.
Front Ophthalmol (Lausanne)
November 2024
Division of Neuro-Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Purpose: To describe a unique presentation of optic neuritis associated with positive HLA-B35.
Observations: A woman presented with unilateral retro-orbital pain, mildly decreased vision, and optic disc edema with new-onset aphthous ulcers. Color vision was preserved, and no visual field deficits were noted.
Crohn's disease after multiple doses of rituximab treatment in a child with refractory nephrotic syndrome and an mutation: a case report.
Front Pediatr
November 2024
Department of Pediatrics, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.
inflammatory bowel disease (IBD) in response to rituximab (RTX) has been documented on multiple occasions as a severe adverse effect. However, none of these reports mentioned any genetic variation associated with this complication. We describe the case of a 16-year-old patient with refractory nephrotic syndrome (NS) diagnosed at the age of 6 years, notably with a heterozygous mutation of the gene, who developed Crohn's disease (CD) following ten administrations of RTX.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!